Does Otrexup Cause Liver Damage with Long-Term Use?
Otrexup, a subcutaneous auto-injector form of methotrexate, carries a boxed warning for hepatotoxicity, including liver damage from chronic use.[1][2] Methotrexate can cause acute elevations in liver enzymes and, over time, lead to fibrosis, cirrhosis, or liver failure, even at low weekly doses used for rheumatoid arthritis or psoriasis.[3]
Patients on long-term therapy (often years) face higher cumulative risk, with studies showing 5-20% developing significant fibrosis after 2-5 years of exposure.[4] Risk rises with total lifetime dose exceeding 1.5-3.5 grams.[1]
How Does Methotrexate Damage the Liver?
It inhibits dihydrofolate reductase, disrupting DNA synthesis and causing hepatocyte toxicity, inflammation, and fat accumulation (steatosis).[2] Chronic exposure triggers stellate cell activation and fibrosis.[5]
Monitoring involves baseline liver function tests (ALT, AST, albumin), then every 1-3 months; biopsy if fibrosis suspected.[1][3]
Who Is at Higher Risk for Liver Injury?
- Alcohol use (even moderate) multiplies risk by 5-10 fold.[1]
- Obesity, diabetes, or viral hepatitis (B/C).[3]
- Older age or concurrent NSAIDs/ other hepatotoxins.[2]
- Genetic factors like MTHFR polymorphisms may impair folate metabolism, worsening toxicity.[5]
Up to 30% of users show transient enzyme elevations; 1-5% discontinue due to persistent issues.[4]
What Monitoring and Prevention Steps Are Required?
FDA guidelines mandate:
- Folate supplementation (1-5 mg daily) to cut hepatotoxicity by 40-80%.[1][3]
- Avoid alcohol; limit to <1 drink/week if approved.[2]
- Serial imaging or FibroScan for non-invasive fibrosis checks.[5]
- Discontinue if fibrosis/circling score ≥3 on biopsy.[1]
Long-term users often switch to biologics if liver risks emerge.[4]
Can Liver Damage Be Reversed?
Early fibrosis may regress after stopping methotrexate, but advanced cirrhosis is often irreversible.[3][5] A 2020 review found 60% of mild cases improved within 6 months of discontinuation.[4]
How Does Otrexup Compare to Oral Methotrexate for Liver Risk?
No difference; both deliver the same drug. Subcutaneous route may improve absorption and reduce GI upset but carries identical hepatotoxicity profile.[2][3]
Alternatives for Long-Term Use if Liver Concerns Arise
| Drug | Liver Risk | Common Use |
|------|------------|------------|
| Leflunomide | Moderate (monitor ALT) | RA |
| Sulfasalazine | Low | RA, IBD |
| Hydroxychloroquine | Very low | RA, lupus |
| Biologics (e.g., adalimumab) | Lowest | RA, psoriasis |
[1]: FDA Otrexup Label
[2]: Drugs.com - Otrexup Side Effects
[3]: American College of Rheumatology Guidelines
[4]: Hepatology 2019 Review on MTX Hepatotoxicity
[5]: UpToDate - Methotrexate-Induced Liver Injury